ClinicalTrials.Veeva

Menu

Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus

S

Sohag University

Status

Not yet enrolling

Conditions

Systemic Lupus Erythematosus (SLE)

Treatments

Other: clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients

Study type

Observational

Funder types

Other

Identifiers

NCT05724940
soh-med-22-12-15

Details and patient eligibility

About

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a highly variable presentation and course. It can affect virtually every organ of the body and many symptoms may be observed. Skin, musculoskeletal, hematologic, and serological involvement are most commonly observed. Some patients show predominately hematologic, renal, or central nervous system manifestations.

Studies have reported that juvenile-onset SLE patients tend to have a more aggressive presentation and course, with higher rates of organ involvement and lower life expectancy than adult-onset SLE patients. Late-onset SLE patients tend to have a more insidious onset of disease and tend to have less major organ involvement and more benign disease course. However, they have a poorer prognosis than patients who developed SLE before the age of 50 years, because of the generally higher frequency of comorbid diseases and higher organ damage, due to aging and longer exposure to ''classical'' vascular risk factors.

Aims of the Study:

To compare clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.

Full description

Methods:

All patients will be subjected to the following:

  1. Thorough medical history of the patients

  2. Full clinical examination including:

    1. General examination and vital signs.
    2. Complete rheumatological examination.
    3. SLE disease activity index SLEDAI (ref).
    4. SLICC damage index (ref).
  3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).

  4. Renal investigations:

    1. Kidney functions
    2. Urine analysis
    3. 24 hours protein in urine and/or A/C ratio
    4. Renal biopsy if indicated.
  5. ANA test.

  6. ANA profile for the most common 19 autoantibodies by immunoblot.

Enrollment

150 estimated patients

Sex

All

Ages

6 months to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Inclusion criteria:

  1. Patients diagnosed as SLE( Systemic lupus erythematosus )according to EULAR / ACE (European League Against Rheumatism /American College of Rheumatology )
  2. Age juvenile SLE ( Systemic lupus erythematosus )was defined as a diagnosis below the age of 18 years, and those diagnosed between 19 and 50 years of age were classified as adult SLE ( Systemic lupus erythematosus ), late onset SLE was defined as a diagnosis at more than 50 years of age).
  3. Patients with a disease duration of more than 6 months

Exclusion criteria

  • Exclusion criteria:

    1. Patients with had other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease , overlap syndrome or primary Sjogren's syndrome ,but not secondary Sjogren's syndrome or secondary antiphospholipid syndrome .
    2. Patients who are not willing to be involved in the study

Trial design

Trial documents
1

Trial contacts and locations

0

Loading...

Central trial contact

hanan sa abozaid, Professor; alaa mo hemdan, assistant

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems